CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Tesamorelin vs Sermorelin vs CJC 1295 Reddit Compared

Real Peptides Research TeamEditorial

Updated September 30, 20269 min read

46 WORDS

Short answer

Almost every tesamorelin vs sermorelin vs CJC 1295 reddit thread argues about which compound is strongest. That's the wrong axis. Three of the four molecules people keep comparing are analogs of the same parent hormone, and the fourth, ipamorelin, doesn't bind the GHRH receptor at all.

Key takeaways

Sermorelin, tesamorelin and CJC-1295 all bind the GHRH receptor, while ipamorelin acts on GHSR-1a, the ghrelin receptor, making it the only non-GHRH compound in the comparison.
Tesamorelin is the only one of the four holding current FDA approval, granted in 2010 for HIV-associated lipodystrophy under the brand name Egrifta.
CJC-1295 with DAC binds albumin and has been reported with a half-life measured in days, while CJC-1295 without DAC clears in roughly 30 minutes.
Sermorelin is GRF(1-29)NH2, the shortest fragment of the 44-residue human GHRH molecule that retains full activity of the parent hormone.
Any protocol or listing that says CJC-1295 without specifying DAC status is describing two pharmacologically different compounds at once.
All four are prohibited in competitive sport under WADA category S2 and are supplied by Real Peptides for laboratory research use only.

Our team fields this question weekly from labs sourcing research material, and the confusion is structural rather than a question of potency.

What is the difference between tesamorelin, sermorelin, CJC-1295 and ipamorelin?

Sermorelin, tesamorelin and CJC-1295 are GHRH (growth hormone-releasing hormone) analogs that bind the GHRH receptor on pituitary somatotroph cells. Ipamorelin is a ghrelin mimetic acting on a separate receptor, GHSR-1a. Half-life is the real separator: sermorelin clears within minutes, while CJC-1295 with DAC has been reported to persist for days.

The common forum framing treats these as four tiers of one drug, weakest to strongest. They aren't. They are two receptor families with very different clearance profiles and completely different regulatory histories, and only one of the four carries FDA approval for any indication. This piece maps sequence origin, reported half-life, receptor target and legal status across all four.

Two receptor families, four molecules

Sermorelin is GRF(1-29)NH2, the first 29 amino acids of the 44-residue endogenous human GHRH molecule, and it is the shortest fragment that retains the full biological activity of the parent hormone. Tesamorelin keeps the entire 44-residue backbone and adds a trans-3-hexenoyl group to the N-terminal tyrosine, a modification that blunts cleavage by dipeptidyl peptidase-4 (DPP-4), the enzyme that degrades native GHRH almost immediately in circulation.

CJC-1295 begins from the same 1-29 fragment but carries four amino acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) that resist enzymatic breakdown. The version sold as CJC-1295 no DAC, also called modified GRF(1-29), stops there. The DAC version adds a maleimidopropionic acid Drug Affinity Complex that binds covalently to albumin in plasma.

Ipamorelin sits outside this family entirely. It's a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that agonises GHSR-1a, the ghrelin receptor, and the literature describes it as unusually selective, with far less effect on ACTH, cortisol and prolactin than earlier GHRPs such as GHRP-6. Because the two receptor pathways are independent, research combining a GHRH analog with a secretagogue is common, which is why blended preparations like CJC-1295 with ipamorelin exist as catalog items at all.

Half-life is the dividing line, not potency

The half-life spread across these four compounds is enormous, and it explains more forum disagreement than anything else. Native GHRH survives only a few minutes in plasma; sermorelin, being a near-identical fragment, clears on a similar timescale. CJC-1295 no DAC, protected by its four substitutions, has been reported in the range of roughly half an hour. Tesamorelin is broadly similar after subcutaneous administration in the published pharmacokinetic literature. CJC-1295 with DAC is the outlier: early clinical work reported terminal half-lives measured in days, not minutes, because albumin binding shields it from renal clearance. Ipamorelin sits in between, with reported values around two hours.

Here's the part most comparison posts skip. Growth hormone is not secreted at a steady rate. It's released in discrete pulses shaped by somatostatin, the inhibitory hormone that switches secretion off between bursts, and downstream signalling is pattern-sensitive. A compound with a multi-day half-life doesn't just produce more of the same signal, it produces a structurally different one, flattening pulsatility into sustained elevation. That distinction is why short-acting analogs like sermorelin remain interesting to researchers modelling physiological secretion, even though a longer-acting molecule looks superior on paper. Our team has watched that single point resolve more sourcing confusion than any potency chart.

Regulatory status separates these four more sharply than pharmacology

Tesamorelin is the only one of the four with current FDA approval. It was approved in 2010 under the brand name Egrifta for reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy, and the registration trials reported meaningful reductions in visceral adipose tissue over roughly 26 weeks. Sermorelin was previously approved in the United States as Geref and was withdrawn from the market in 2008 for commercial rather than safety reasons; it now circulates mainly through compounding channels. CJC-1295 and ipamorelin have never held FDA approval for any indication, and the FDA has grouped both among bulk drug substances it considers to raise significant safety concerns for pharmacy compounding. All four are prohibited in sport under the World Anti-Doping Agency's S2 category.

That gap matters for anyone sourcing material. Every compound in our growth hormone secretagogue collection, including tesamorelin and ipamorelin, is supplied strictly for laboratory research use, is not a drug product, and is never sold for human or veterinary consumption. Third-party certificates of analysis document identity and purity per batch. Anything in this article is educational and research-framed only, and questions about clinical or animal use belong with a licensed physician or veterinarian rather than a forum thread.

Tesamorelin vs Sermorelin vs CJC 1295 Reddit Threads: Side-by-Side Comparison

This table maps the four compounds (five, counting both CJC-1295 forms) across the attributes that actually differentiate them. Reported half-life values come from published pharmacokinetic literature and vary by route and population.

Compound	Sequence origin	Reported half-life	Receptor target	Regulatory status	Bottom line for research sourcing
Sermorelin	GRF(1-29)NH2, the first 29 residues of endogenous human GHRH	Minutes, closely tracking native GHRH	GHRH receptor on pituitary somatotrophs	Formerly approved as Geref, withdrawn from the US market in 2008 for commercial reasons	The closest analog to the native hormone, which makes it the reference point for pulsatile secretion models rather than a weak version of the others
Tesamorelin	Full 44-residue GHRH with a trans-3-hexenoyl group on the N-terminal tyrosine	Short, roughly comparable to other unmodified-duration GHRH analogs after subcutaneous delivery	GHRH receptor	The only compound of the four with current FDA approval, granted 2010 for HIV-associated lipodystrophy	The best-documented molecule in the group, with registration-quality trial data behind its visceral adipose tissue endpoint
CJC-1295 no DAC (mod GRF 1-29)	GRF(1-29) with four substitutions: D-Ala2, Gln8, Ala15, Leu27	Approximately 30 minutes in reported data	GHRH receptor	No FDA approval; flagged by FDA among bulk substances raising compounding safety concerns	Behaves like a protease-resistant sermorelin, which is why protocols listing plain CJC-1295 are ambiguous without the DAC status specified
CJC-1295 with DAC	Same four substitutions plus a maleimidopropionic acid complex binding albumin	Reported in days rather than minutes in early clinical work	GHRH receptor	No FDA approval; same compounding restrictions as the no-DAC form	The pharmacokinetic outlier of the group, producing sustained rather than pulsatile exposure, a genuinely different research question
Ipamorelin	Synthetic pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, unrelated to GHRH	Around two hours in reported data	GHSR-1a, the ghrelin receptor	No FDA approval; prohibited in sport under WADA category S2	Not a GHRH analog at all, and its selectivity relative to older GHRPs is the reason it appears in nearly every blend

What If: Sourcing and Handling Scenarios

What if a paper or listing says CJC-1295 with no mention of DAC?

Treat the identity as unresolved until the certificate of analysis confirms it. The DAC and no-DAC forms share the same tetrasubstituted GRF(1-29) core but differ by a half-life of minutes versus days, which makes them non-interchangeable in any experimental design. Vendors and forum posts use the bare name for both, and this single ambiguity is responsible for a large share of contradictory reports in every tesamorelin vs sermorelin vs CJC 1295 reddit discussion.

What if a lyophilised vial arrives warmer than expected?

Document the excursion, photograph the vial and contact the supplier before proceeding. Lyophilised peptides are generally stable at ambient temperature for short shipping windows, which is why cold packs are a precaution rather than an absolute requirement, but sustained heat can compromise peptide integrity in ways that visual inspection cannot detect. A reputable supplier will provide batch documentation and replace material where the cold chain clearly failed.

What if the compound behaves differently across two batches?

Compare certificates of analysis for both lots before changing anything else in the experimental design. Purity, residual solvent content and net peptide content all vary between synthesis runs, and net peptide content in particular is frequently overlooked because the label weight includes counter-ions and residual water. This is the reason our small-batch synthesis process publishes per-batch analytics rather than a single generic specification sheet.

What if a supplier cannot produce a third-party certificate of analysis?

Do not proceed with that material for research purposes. HPLC and mass spectrometry results from an independent laboratory are the only practical way to confirm that a vial contains the sequence on the label at the stated purity. Without them, batch-to-batch variability becomes an uncontrolled variable, and any result generated is unpublishable. Our full research catalog is documented on this basis.

The Unglamorous Truth About Comparing These Four Compounds

Here's the honest answer: there is no ranking. Anyone presenting these four as a ladder from sermorelin up to tesamorelin is describing marketing hierarchy, not pharmacology. Tesamorelin has the strongest published evidence base because it went through registration trials for a specific indication, not because it's a stronger version of sermorelin. CJC-1295 with DAC isn't an upgrade, it's a different exposure pattern with different implications. And ipamorelin isn't a competitor to any of them, it's a compound acting on a separate receptor that happens to produce an overlapping endpoint. Pick by research question, not by tier.

The tesamorelin vs sermorelin vs CJC 1295 reddit consensus keeps reforming around whichever compound was discussed most recently, which is exactly what happens when a class of molecules gets compared on a single axis that doesn't exist. Sequence origin tells you what a molecule is. Half-life tells you what kind of signal it produces. Regulatory status tells you what evidence actually exists behind it. Line those three up across all four compounds and the debate stops being a debate, because the compounds stop competing with each other and start answering separate questions.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Sermorelin is GRF(1-29)NH2, the first 29 amino acids of endogenous human GHRH, with no protective modification. Tesamorelin retains the full 44-residue GHRH sequence and adds a trans-3-hexenoyl group to the N-terminal tyrosine, which resists degradation by the enzyme DPP-4. Tesamorelin is also the only compound in this class with current FDA approval, granted in 2010 for HIV-associated lipodystrophy.

No. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that agonises GHSR-1a, the ghrelin receptor, which is a completely separate pathway from the GHRH receptor targeted by sermorelin, tesamorelin and CJC-1295. The literature describes ipamorelin as more selective than older secretagogues such as GHRP-6, with less associated effect on cortisol and prolactin.

Three reasons dominate. First, CJC-1295 is routinely discussed without specifying whether the DAC version is meant, and the two forms differ in half-life by days versus minutes. Second, most anecdotal posts have no certificate of analysis behind the material being described. Third, the four compounds are compared as if they sit on one potency scale when they span two different receptor families.

CJC-1295 with DAC, by a wide margin. The Drug Affinity Complex binds covalently to albumin in plasma, shielding the peptide from renal clearance, and early clinical pharmacokinetic work reported terminal half-lives measured in days. By comparison, sermorelin clears in minutes, CJC-1295 without DAC in roughly 30 minutes, and ipamorelin in around two hours.

Real Peptides supplies these compounds strictly for laboratory research use by researchers and institutions. They are not FDA-approved drug products, are not sold for human or veterinary consumption, and are not accompanied by dosing or administration guidance. Anyone with questions about clinical or animal applications should raise them with a licensed physician or veterinarian.

Pricing varies widely by compound, vial size and purity documentation, and blended preparations are generally priced differently from single compounds. The more meaningful cost question is what documentation comes with the vial. Material without third-party HPLC and mass spectrometry results is cheaper for a reason, and the saving disappears the moment a batch discrepancy invalidates an experiment.

Neither compound has completed the full FDA approval process for any indication, and the FDA has grouped both among bulk drug substances it considers to raise significant safety concerns for pharmacy compounding. That regulatory position reflects limited long-term human safety data rather than any single documented hazard. Both are also prohibited in competitive sport under WADA category S2.

They act on two distinct receptors: CJC-1295 on the GHRH receptor and ipamorelin on GHSR-1a. Because the pathways are independent, research literature on GHRH analogs combined with secretagogues has consistently reported greater growth hormone release from the combination than from either agent alone. That mechanistic rationale is why blended research preparations exist, though combination data specific to these two compounds remains limited.

Not currently. Sermorelin was marketed in the United States as Geref and was withdrawn from the market in 2008 for commercial reasons rather than safety findings. It has since reappeared largely through compounding pharmacies, which means the material circulating today does not carry the same finished-product oversight the original approved formulation did.

There is no stable consensus, and that instability is informative. Forum preference tends to track whichever compound is most available and most discussed at a given moment rather than the underlying evidence. On published data alone, tesamorelin is the best-documented of the four because it completed registration trials, but that reflects its regulatory path, not superiority across every research question.

At minimum, it should confirm identity by mass spectrometry, purity by HPLC, and net peptide content, which is the actual peptide mass excluding counter-ions and residual water. Batch-specific results matter more than a generic product specification sheet, because purity and net content vary between synthesis runs even from the same supplier.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA